Thu, Nov 21, 2024
[Archive]
Volume 14, Issue 1 ( March 2022 2022)
Iranian Journal of Blood and Cancer 2022, 14(1): 18-22 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hussein M M, Mohammed H S. Clinical and Pathological Features of Iraqi Patients with Prostate Cancer. Iranian Journal of Blood and Cancer 2022; 14 (1) :18-22
URL: http://ijbc.ir/article-1-1246-en.html
URL: http://ijbc.ir/article-1-1246-en.html
1- Department of Optical Technology, College of Health and Medical Technique, Middle Technical University, Iraq
2- Department of Medical Instrumentaion Engineering Techniques, Electrical Engineering Technical College, Middle Technical University, Iraq
2- Department of Medical Instrumentaion Engineering Techniques, Electrical Engineering Technical College, Middle Technical University, Iraq
Abstract: (1834 Views)
Background: The clinical pathological features were detected by measuring the prostatic acid phosphatase (PAP) activity according to the stages and grades of prostate cancer. We also explored the relationship between the disease and age with family history among the patients.
Methods: Data were collected from direct interview and from the patient’s records. Blood samples that collected before the surgery from Baghdad hospitals. By using the ELISA device, PAP enzyme activity was determinred using Automated Chemiluminescent Immunometric Assay.
Result: Older individuals were more likely to develop prostate cancer since out of the 50 samples collected, most (46%) were ≥60 years old. 23 (46%) cases were in stage II of PCa and 29 (58%) had grade-II as the most dominant stage and grade. Family history from parents to sons had a significant role in the possibility of being positive for prostate cancer. A positive family history was found in 72% of the cases of PCa, and it was found that the enzymatic activity of the PAP enzyme rises in the presence of prostate cancer.
Conclusion: PAP enzyme is reliable in diagnosing the presence of prostate cancer, as the increase in the activity of the enzyme PAP coincides with the presence of prostate cancer.
Methods: Data were collected from direct interview and from the patient’s records. Blood samples that collected before the surgery from Baghdad hospitals. By using the ELISA device, PAP enzyme activity was determinred using Automated Chemiluminescent Immunometric Assay.
Result: Older individuals were more likely to develop prostate cancer since out of the 50 samples collected, most (46%) were ≥60 years old. 23 (46%) cases were in stage II of PCa and 29 (58%) had grade-II as the most dominant stage and grade. Family history from parents to sons had a significant role in the possibility of being positive for prostate cancer. A positive family history was found in 72% of the cases of PCa, and it was found that the enzymatic activity of the PAP enzyme rises in the presence of prostate cancer.
Conclusion: PAP enzyme is reliable in diagnosing the presence of prostate cancer, as the increase in the activity of the enzyme PAP coincides with the presence of prostate cancer.
: Original Article |
Subject:
Gastroentrology
Received: 2022/04/30 | Accepted: 2022/03/10 | Published: 2022/04/30
Received: 2022/04/30 | Accepted: 2022/03/10 | Published: 2022/04/30
References
1. Prashanth Anamthathmakula and Wipawee Winuthayanon Mechanism of semen liquefaction and its potential for a novel non-hormonal contraception†2020 Aug; 103(2): 411-426.Published online 2020 May 14. [DOI:10.1093/biolre/ioaa075]
2. Verze P, Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. Nat Rev Urol 2016; 13:379-386. [DOI:10.1038/nrurol.2016.89]
3. Drabovich AP, Saraon P, Jarvi K, Diamandis EP. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol 2014; 11:278-288. [DOI:10.1038/nrurol.2014.74]
4. Kim EH, Larson JA, Andriole GL (2016). "Management of Benign Prostatic Hyperplasia". AnnualReviewofMedicine (Review). [DOI:10.1146/annurev-med-063014-123902]
5. Üçer O (1 December 2011). "Giant prostatic hyperplasia: Case report and literature review". Dicle Medical Journal / Dicle Tıp Dergisi. 38 (4): 489-491. [DOI:10.5798/diclemedj.0921.2011.04.0072]
6. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-9. [DOI:10.1016/S0022-5347(17)49698-4]
7. Xia SJ, Xu XX, Teng JB, Xu CX, Tang XD. Characteristic pattern of human prostatic growth with age. Asian J Androl. 2002;4:269-71.
8. McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2:35 49. [DOI:10.1002/pros.2990020105]
9. Korček, M., Sekerešová, M., Makarevich, A. V., Gavurová, H., Olexíková, L., Pivko, J., Barreto, L."Morphological and functional alterations of the prostate tissue during clinical progression in hormonally naïve, hormonally treated and castration resistant patients with metastatic prostate cancer". Oncology Letters 20.5 (2020): 201. [DOI:10.3892/ol.2020.12064]
10. Shi-Jun Zhang,Hai-Ning Qian, Yan Zhao, Kai Sun, Hui-Qing Wang, Guo-Qing Liang,Feng-Hua Li, and Zheng LiRelationship between age and prostate sizeAsian J Androl. 2013 Jan; 15(1): 116-120. Published online 2012 Dec 10 [DOI:10.1038/aja.2012.127]
11. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61:267-73. [DOI:10.1016/S0090-4295(02)02371-3]
12. Yiyu Huang , Jiaxin LI , Shan Yang , Daozhang Yuan and Shusheng Wang ,Efficacy and safety of transurethral split of prostate for benign prostatic hyperplasia: a meta-analysis Huang et al. BMC Urology (2020) 20:141. [DOI:10.1186/s12894-020-00704-4]
13. Skinder D, Zacharia I, Studin J, Covino J. Benign prostatic hyperplasia. J Am Acad Physician Assist. 2016;29(8):19-23. [DOI:10.1097/01.JAA.0000488689.58176.0a]
14. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122-8.
15. Luigi Cormio, ,Beppe Calò, Ugo Falagario, Manuela Iezzi, Alessia Lamolinara, Paola Vitaglione, Giovanni Silecchia, Giuseppe Carrieri, Vincenzo Fogliano, Stefano Iacobelli, Pier Giorgio Natali & Mauro Piantelli Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebocontrolled studyJournal of Translational Medicine volume 19, Article number: 24 (2021) [DOI:10.1186/s12967-020-02684-3]
16. Christopher J McNally, Mark W Ruddock, Tara Moore, and Declan J McKenna Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature ReviewCancer Manag Res. 2020 . 12: 5225-5241.Published online 2020 Jul. [DOI:10.2147/CMAR.S250829]
17. Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the populationbased Krimpen-study: prediction of future prostate volume in individual men. Prostate.
18. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009;182:1458-62. [DOI:10.1016/j.juro.2009.06.047]
19. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon. 2013. http:// globocan.iarc.fr. Accessed 24 May 2018.
20. DeVita VT Jr, Lawrence TS, Rosenberg SA (eds): Cancer of the prostate, in Cancer: Principles and Practice of Oncology (ed 11). Philadelphia, PA, Wolters Kluwer, 2019, 1087.
21. James A. Eastham, MD ; Glenn Heller, PhD ; Susan Halabi, PhD ; J. Paul Monk III, MD ; Himisha Beltran, MD; Martin Gleave, MD, Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer; Journal of Clinical Oncology > List of Issues > Volume 38, Issue 26 > ORIGINAL REPORTS Genitourinary Cancer ... J Clin Oncol. 2020 Sep 10;volume38(26):3042-3050. [DOI:10.1200/JCO.20.00315]
22. Dess RT, Hartman HE, Mahal BA, et al. Association of black race with prostate cancer-specific and othercause mortality. JAMA Oncol 2019;5:975-983. [DOI:10.1001/jamaoncol.2019.0826]
23. Mahal BA, Alshalalfa M, Spratt DE, et al. Prostate cancer genomic-risk differences between AfricanAmerican and white men across Gleason scores. Eur Urol 2019;75:1038-1040. [DOI:10.1016/j.eururo.2019.01.010]
24. Brandon A. Mahal, M.D ,Mohammed Alshalalfa, Ph.D. Kevin H. Kensler, Sc.D. Ilkania ChowdhuryPaulino, B.A. Racial Differences in Genomic Profiling of Prostate Cancer The New England Journal of Medicine Downloaded from nejm.org on August 24, 2021. For personal use only. No othN Engl J Med2020;383:1083-1085. [DOI:10.1056/NEJMc2000069]
25. Alyssa N. Troeschel, MPH, Terryl J. Hartman, PhD, MPH, RD, Eric J. Jacobs, PhD, Victoria L. Stevens, PhD, Ted Gansler, MD, MPH," Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer" J Clin Oncol. 22020 Jun 20; 38(18): 2018- 2027. Published online 2020 Apr 6. [DOI:10.1200/JCO.19.02185]
26. Husson O, van Steenbergen LN, Koldewijn EL, et al. : Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis. BJU Int 114:691-697, 2014. [DOI:10.1111/bju.12519]
27. Muniyan, Sakthivel; Chaturvedi, Nagendra K.; Dwyer, Jennifer G.; LaGrange, Chad A.; Chaney, William G.; and Lin, Ming-Fong, "Human prostatic Acid phosphatase: structure, function and regulation." (2013). Journal Articles: Biochemistry & Molecular Biology. Paper 46 [DOI:10.3390/ijms140510438]
28. P. Vihko, M. Kontturi, and L. K. Korhonen, "Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I," Clinical Chemistry, vol. 24, no. 3, pp. 466- 470, 1978. [DOI:10.1093/clinchem/24.3.466]
29. Luchter-Wasyl E., Ostrowski W. Subunit structure of human prostatic acid phosphatase. Biochim. Biophys. Acta. 1974;365:349-359. [DOI:10.1016/0005-2795(74)90008-7]
30. M. F. Lin, M.-S. Lee, X.-W. Zhou et al., "Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells," The Journal of Urology, vol. 166, no. 5, pp. 1943-1950, 2001. [DOI:10.1016/S0022-5347(05)65725-4]
31. Taira A, Merrick G, Wallner K, Dattoli M. Reviving the acid phosphatase test for prostate cancer. Oncology. 2007; 21:1003-10.
32. Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I. et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, Accessed 02 February 2019. [Internet]
33. Perdana NR, Mochtar CA, Umbas R, Hamid AR. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. Acta Med Indones. 2016;48(3):228-238.
34. SEER Cancer Statistics Review, 1975-2013 [Internet]. National Cancer Institue, Bethesda, MD. 2016. Available from: https://seer.cancer.gov/csr/1975_2015/. Accessed 04 February 2019. [Internet]. SEER, 2018.
35. Moyad, M.A.; Newton, R.U.; Tunn, U.W.; Gruca, D. Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy. Res. Rep. Urol. 2016, 8, 133-143. [DOI:10.2147/RRU.S107852]
36. Rawla, P. Epidemiology of Prostate Cancer. World J. Oncol. 2019, 10, 63-89 [DOI:10.14740/wjon1191]
37. Carroll PR, Grossfeld GD, editors. Prostate cancer. Hamilton, London: Decker Inc.; 2002.
38. Sridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD. Association between family history of prostate cancer. JMH. 2010;7:45-54 [DOI:10.1016/j.jomh.2009.10.006]
39. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study Ola Bratt, Linda Drevin, Olof Akre, Hans Garmo, Par StattinJNCI J Natl Cancer Inst (2016) 108(10): djw11oi: 10.1093/jnci/ djw110 Fi0 [DOI:10.1093/jnci/djw110]
40. Jun Li, Joseph A. Djenaba, Ashwini Soman, Sun Hee Rim, and Viraj A. Master Recent Trends in Prostate Cancer Incidence by Age, Cancer Stage, and Grade, the United States, 2001-2007Prostate Cancer. 2012; 2012: 691380. Published online 2012 Nov 27. doi: 10.1155/2012/691380 PMCID: PMC3515924 PMID: 23251806 [DOI:10.1155/2012/691380]
41. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer. 2009;115(13):2863-2871. [DOI:10.1002/cncr.24324]
42. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. Journal of Clinical Oncology. 2010;28(7):1117-1123. [DOI:10.1200/JCO.2009.26.0133]
43. A. B. Gutman and E. B. Gutman, "An "acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland," The Journal of Clinical Investigation, vol. 17, no. 4, pp. 473-478, 1938. [DOI:10.1172/JCI100974]
44. J. A. Whitesel, R. E. Donohue, J. H. Mani et al., "Acid phosphatase: its influence on the management of carcinoma of the prostate," The Journal of Urology, vol. 131, no. 1, pp. 70-71, 1984. [DOI:10.1016/S0022-5347(17)50207-4]
45. H. Y. Kong and J. Byun, "Emerging roles of human prostatic acid phosphatase," Biomolecules & Therapeutics, vol. 21, no. 1, pp. 10-20, 2013. [DOI:10.4062/biomolther.2012.095]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
